within Pharmacolibrary.Drugs.ATC.C;

model C10BA09
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.2,
    Cl             = 0.0002,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.053,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C10BA09</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Rosuvastatin and fenofibrate is a fixed-dose combination medication that includes rosuvastatin, a statin used to lower cholesterol and reduce cardiovascular risk, and fenofibrate, a fibrate that lowers triglycerides and increases HDL cholesterol. This combination is used in the management of mixed dyslipidemia and hyperlipidemia, and is currently approved for clinical use in various countries.</p><h4>Pharmacokinetics</h4><p>No published clinical pharmacokinetic (PK) population or compartmental model specific to the fixed-dose combination of rosuvastatin and fenofibrate was identified. PK parameters are estimated based on available literature for the individual components when administered orally in healthy adult subjects.</p><h4>References</h4><ol><li><p>Kosoglou, T, et al., &amp; Alton, KB (2005). Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. <i>Clinical pharmacokinetics</i> 44(5) 467–494. DOI:<a href=\"https://doi.org/10.2165/00003088-200544050-00002\">10.2165/00003088-200544050-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/15871634/\">https://pubmed.ncbi.nlm.nih.gov/15871634</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C10BA09;
